COVID-19 SARS-CoV-2 semi-quantitative antibody, IgG, spike

Alphabetical Test listing

COVID-19 SARS-CoV-2 semi-quantitative antibody, IgG, spike-994

  
COVID-19 SARS-CoV-2 semi-quantitative antibody, IgG, spike
  
994
  
LAB994
  
MSO
  
COVID
COVID-19
COVID-19 spike RBD antibody & titer reflex
S protein
SARS-CoV-2 Semi-Quantitative IgG Antibody, Spike
Severe Acute Respiratory Syndrome (SARS)
Spike
  

Qualitative detection of IgG antibodies to SARS-CoV-2, the virus that causes COVID-19, to help identify individuals who have been exposed to the virus. Serologic results should not be used as the sole basis to diagnose or exclude recent SARS-CoV-2 infection. This test is recommended in individuals at least 10 days post symptom onset or following exposure to individuals with confirmed COVID-19.

The incubation period for COVID-19 ranges from 5 to 7 days. Current literature suggests that detectable IgG-class antibodies against SARS-CoV-2 develop approximately 8 to 11 days following onset of symptoms. Correlation with epidemiologic risk factors and other clinical and laboratory findings is recommended. A positive serological result is not diagnostic but indicates that an individual has likely been infected with SARS-CoV-2 and produced an immune response to the virus. It is not known at this time whether detectable antibody correlates with immunity. A negative serologic result indicates that an individual has not developed detectable antibodies at the time of testing. While contingent on a variety of factors, this could be due to testing too early in the course of infection, the absence of exposure to the virus, or the lack of adequate immune response, which can be due to conditions or treatments that suppress immune function.

  
Serum
  
  
0.5 mL
  

Spin

  

Gold serum separator (SST) tube

  
EDTA plasma
Lithium heparin (Li hep) plasma
  

Lavender (EDTA):

Immediatley following collection, mix sample by inverting 8 - 10 times to prevent clotting.

Dk green Sodium heparin (Li hep), no gel:

Immediately following collection, mix sample by inverting 5 - 10 times to prevent clotting.

Lt green plasma separator (PST):

Immediately follow collection, mix sample by inverting 8 - 10 times to prevent clotting

  

Red:

  1. Allow specimen to clot
  2. Spin
  3. Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum within two (2) hours of sample collection

Lavender (EDTA):

  1. Spin
  2. Transfer plasma to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as EDTA plasma within two (2) hours of sample collection

Dk green Lithium heparin (Li hep), no gel:

  1. Spin
  2. Transfer plasma to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as Li heparin plasma within two (2) hours of sample collection

Lt green plasma separator (PST):

  1. Spin within two (2) hours of sample collection
  

Transfer vial/tube with cap - 12mL (LabCorp)

Lt green plasma separator (PST)

  

Ambient (preferred) – 14 days

Refrigerated – 14 days

Frozen – 14 days

Freeze/thaw cycles - Stable x3

  
  • Gross hemolysis
  • Gross lipemia
  • Visible microbial contamination
  
LabCorp Burlington (164055): R-NX
  
Mo - Fr
  
1 - 3 days
  

Chemiluminescent Immunoassay (CLIA)

  

Negative (<13.0 AU/mL)

  • Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
  • Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
  • Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
  

The incubation period for COVID-19 ranges from 5 to 7 days. Current literature suggests that detectable IgG-class antibodies against SARS-CoV-2 develop approximately 8 to 11 days following onset of symptoms. Correlation with epidemiologic risk factors and other clinical and laboratory findings is recommended. A positive serological result is not diagnostic but indicates that an individual has likely been infected with SARS-CoV-2 and produced an immune response to the virus. It is not known at this time whether detectable antibody correlates with immunity. A negative serologic result indicates that an individual has not developed detectable antibodies at the time of testing. While contingent on a variety of factors, this could be due to testing too early in the course of infection, the absence of exposure to the virus, or the lack of adequate immune response, which can be due to conditions or treatments that suppress immune function.

  
86769
  
01/19/2021
  
11/24/2021
  
11/08/2021